Smarter Decisions,
Better Care

UpToDate synthesizes the most recent medical information into evidence-based practical recommendations clinicians trust to make the right point-of-care decisions.

  • Rigorous editorial process: Evidence-based treatment recommendations
  • World-Renowned physician authors: over 5,100 physician authors and editors around the globe
  • Innovative technology: integrates into the workflow; access from EMRs

Choose from the list below to learn more about subscriptions for a:


Subscribers log in here


Maternal endocrine and metabolic adaptation to pregnancy

INTRODUCTION

The pregnant woman undergoes profound anatomic and physiologic changes in almost every organ system. These adaptations to the pregnant state begin just after conception and evolve through delivery, after which they almost completely revert back to the nonpregnant state over a period of weeks. The purpose of these alterations is to accommodate the needs of the maternal-fetal unit.

The normal metabolic and endocrinologic changes in pregnancy will be reviewed here. Metabolic and endocrinologic diseases complicating pregnancy are discussed separately.

ENDOCRINE ADAPTATIONS

Maternal endocrine adaptations to pregnancy involve the hypothalamus, pituitary, parathyroid, thyroid, adrenal glands, and ovary, and are linked to the interactions of the fetal-placental-maternal unit.

Hypothalamic hormones — The hypothalamus regulates much of the endocrine system by coordinating input from multiple areas and output via the hypothalamic-pituitary axis through cell to cell communication (paracrine signaling) and within the same cell communication (autocrine signaling). This axis directly affects the function of the thyroid gland, the adrenal gland, and the gonads and influences growth, lactation, and water balance (table 1) [1,2]. An intact hypothalamus is necessary for natural conception; however, it is not essential when assisted reproductive techniques are being employed as long as full hormone replacement therapy is administered [3]. (See "Hypothalamic-pituitary axis".)

The hypothalamic stimulatory hormones are gonadotropin-releasing hormone (GnRH), corticotropin-releasing hormone (CRH), growth hormone-releasing hormone (GHRH), thyrotropin-releasing hormone (TRH), and prolactin-releasing factors. Somatostatin and prolactin-inhibiting factors are inhibitory hypothalamic hormones. These hormones are present at high concentrations in the portal circulation where they are biologically active, but are almost nondetectable in the systemic circulation of nonpregnant women. However, the circulating concentrations of many of these hormones rise during pregnancy due to placental production of identical or variant hormones.

               

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Nov 2014. | This topic last updated: Jan 6, 2014.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2014 UpToDate, Inc.
References
Top
  1. Chrousos GP. The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation. N Engl J Med 1995; 332:1351.
  2. Krieger DT. Brain peptides: what, where, and why? Science 1983; 222:975.
  3. Volz J, Heinrich U, Volz-Köster S. Conception and spontaneous delivery after total hypophysectomy. Fertil Steril 2002; 77:624.
  4. Stojilkovic SS, Reinhart J, Catt KJ. Gonadotropin-releasing hormone receptors: structure and signal transduction pathways. Endocr Rev 1994; 15:462.
  5. Petraglia F, Florio P, Nappi C, Genazzani AR. Peptide signaling in human placenta and membranes: autocrine, paracrine, and endocrine mechanisms. Endocr Rev 1996; 17:156.
  6. Siler-Khodr TM, Khodr GS, Valenzuela G. Immunoreactive gonadotropin-releasing hormone level in maternal circulation throughout pregnancy. Am J Obstet Gynecol 1984; 150:376.
  7. Petraglia F, Woodruff TK, Botticelli G, et al. Gonadotropin-releasing hormone, inhibin, and activin in human placenta: evidence for a common cellular localization. J Clin Endocrinol Metab 1992; 74:1184.
  8. Siler-Khodr TM, Khodr GS. Content of luteinizing hormone-releasing factor in the human placenta. Am J Obstet Gynecol 1978; 130:216.
  9. Kelly AC, Rodgers A, Dong KW, et al. Gonadotropin-releasing hormone and chorionic gonadotropin gene expression in human placental development. DNA Cell Biol 1991; 10:411.
  10. Bale TL, Vale WW. CRF and CRF receptors: role in stress responsivity and other behaviors. Annu Rev Pharmacol Toxicol 2004; 44:525.
  11. Frim DM, Emanuel RL, Robinson BG, et al. Characterization and gestational regulation of corticotropin-releasing hormone messenger RNA in human placenta. J Clin Invest 1988; 82:287.
  12. Petraglia F, Tabanelli S, Galassi MC, et al. Human decidua and in vitro decidualized endometrial stromal cells at term contain immunoreactive corticotropin-releasing factor (CRF) and CRF messenger ribonucleic acid. J Clin Endocrinol Metab 1992; 74:1427.
  13. Petraglia F, Potter E, Cameron VA, et al. Corticotropin-releasing factor-binding protein is produced by human placenta and intrauterine tissues. J Clin Endocrinol Metab 1993; 77:919.
  14. Petraglia F, Sawchenko PE, Rivier J, Vale W. Evidence for local stimulation of ACTH secretion by corticotropin-releasing factor in human placenta. Nature 1987; 328:717.
  15. Florio P, Franchini A, Reis FM, et al. Human placenta, chorion, amnion and decidua express different variants of corticotropin-releasing factor receptor messenger RNA. Placenta 2000; 21:32.
  16. Majzoub JA, McGregor JA, Lockwood CJ, et al. A central theory of preterm and term labor: putative role for corticotropin-releasing hormone. Am J Obstet Gynecol 1999; 180:S232.
  17. Reis FM, Fadalti M, Florio P, Petraglia F. Putative role of placental corticotropin-releasing factor in the mechanisms of human parturition. J Soc Gynecol Investig 1999; 6:109.
  18. Matthews SG, Gibb W, Lye SJ. Endocrine and paracrine regulation of birth at term and preterm. Endocr Rev 2000; 21:514.
  19. Florio P, Vale W, Petraglia F. Urocortins in human reproduction. Peptides 2004; 25:1751.
  20. Imperatore A, Florio P, Torres PB, et al. Urocortin 2 and urocortin 3 are expressed by the human placenta, deciduas, and fetal membranes. Am J Obstet Gynecol 2006; 195:288.
  21. Mazlan M, Spence-Jones C, Chard T, et al. Circulating levels of GH-releasing hormone and GH during human pregnancy. J Endocrinol 1990; 125:161.
  22. Eriksson L, Frankenne F, Edèn S, et al. Growth hormone 24-h serum profiles during pregnancy--lack of pulsatility for the secretion of the placental variant. Br J Obstet Gynaecol 1989; 96:949.
  23. Lønberg U, Damm P, Andersson AM, et al. Increase in maternal placental growth hormone during pregnancy and disappearance during parturition in normal and growth hormone-deficient pregnancies. Am J Obstet Gynecol 2003; 188:247.
  24. Bajoria R, Babawale M. Ontogeny of endogenous secretion of immunoreactive-thyrotropin releasing hormone by the human placenta. J Clin Endocrinol Metab 1998; 83:4148.
  25. Roti E, Gnudi A, Braverman LE, et al. Human cord blood concentrations of thyrotropin, thyroglobulin, and iodothyronines after maternal administration of thyrotropin-releasing hormone. J Clin Endocrinol Metab 1981; 53:813.
  26. Lee JH, Miele ME, Hicks DJ, et al. KiSS-1, a novel human malignant melanoma metastasis-suppressor gene. J Natl Cancer Inst 1996; 88:1731.
  27. Roseweir AK, Millar RP. The role of kisspeptin in the control of gonadotrophin secretion. Hum Reprod Update 2009; 15:203.
  28. Seminara SB, Messager S, Chatzidaki EE, et al. The GPR54 gene as a regulator of puberty. N Engl J Med 2003; 349:1614.
  29. Bilban M, Ghaffari-Tabrizi N, Hintermann E, et al. Kisspeptin-10, a KiSS-1/metastin-derived decapeptide, is a physiological invasion inhibitor of primary human trophoblasts. J Cell Sci 2004; 117:1319.
  30. Horikoshi Y, Matsumoto H, Takatsu Y, et al. Dramatic elevation of plasma metastin concentrations in human pregnancy: metastin as a novel placenta-derived hormone in humans. J Clin Endocrinol Metab 2003; 88:914.
  31. Torricelli M, Galleri L, Voltolini C, et al. Changes of placental Kiss-1 mRNA expression and maternal/cord kisspeptin levels at preterm delivery. Reprod Sci 2008; 15:779.
  32. Dinç H, Esen F, Demirci A, et al. Pituitary dimensions and volume measurements in pregnancy and post partum. MR assessment. Acta Radiol 1998; 39:64.
  33. Mirlesse V, Frankenne F, Alsat E, et al. Placental growth hormone levels in normal pregnancy and in pregnancies with intrauterine growth retardation. Pediatr Res 1993; 34:439.
  34. Mastorakos G, Ilias I. Maternal hypothalamic-pituitary-adrenal axis in pregnancy and the postpartum period. Postpartum-related disorders. Ann N Y Acad Sci 2000; 900:95.
  35. Meulenberg PM, Hofman JA. Differences between concentrations of salivary cortisol and cortisone and of free cortisol and cortisone in plasma during pregnancy and postpartum. Clin Chem 1990; 36:70.
  36. Glinoer D. What happens to the normal thyroid during pregnancy? Thyroid 1999; 9:631.
  37. Brent GA. Maternal thyroid function: interpretation of thyroid function tests in pregnancy. Clin Obstet Gynecol 1997; 40:3.
  38. Tyson JE, Hwang P, Guyda H, Friesen HG. Studies of prolactin secretion in human pregnancy. Am J Obstet Gynecol 1972; 113:14.
  39. Musey VC, Collins DC, Musey PI, et al. Long-term effect of a first pregnancy on the secretion of prolactin. N Engl J Med 1987; 316:229.
  40. Wilson JF. Levels of alpha-melanotrophin in the human fetal pituitary gland throughout gestation, in adult pituitary gland and in human placenta. Clin Endocrinol (Oxf) 1982; 17:233.
  41. Vaughan Jones SA, Black MM. Pregnancy dermatoses. J Am Acad Dermatol 1999; 40:233.
  42. Lindheimer MD, Barron WM, Davison JM. Osmotic and volume control of vasopressin release in pregnancy. Am J Kidney Dis 1991; 17:105.
  43. Davison JM, Shiells EA, Philips PR, Lindheimer MD. Serial evaluation of vasopressin release and thirst in human pregnancy. Role of human chorionic gonadotrophin in the osmoregulatory changes of gestation. J Clin Invest 1988; 81:798.
  44. Davison JM, Sheills EA, Philips PR, et al. Metabolic clearance of vasopressin and an analogue resistant to vasopressinase in human pregnancy. Am J Physiol 1993; 264:F348.
  45. DeVane GW. Vasopressin levels during pregnancy and labor. J Reprod Med 1985; 30:324.
  46. Leake RD, Weitzman RE, Glatz TH, Fisher DA. Plasma oxytocin concentrations in men, nonpregnant women, and pregnant women before and during spontaneous labor. J Clin Endocrinol Metab 1981; 53:730.
  47. Seki K, Makimura N, Mitsui C, et al. Calcium-regulating hormones and osteocalcin levels during pregnancy: a longitudinal study. Am J Obstet Gynecol 1991; 164:1248.
  48. Seely EW, Brown EM, DeMaggio DM, et al. A prospective study of calciotropic hormones in pregnancy and post partum: reciprocal changes in serum intact parathyroid hormone and 1,25-dihydroxyvitamin D. Am J Obstet Gynecol 1997; 176:214.
  49. Cross NA, Hillman LS, Allen SH, et al. Calcium homeostasis and bone metabolism during pregnancy, lactation, and postweaning: a longitudinal study. Am J Clin Nutr 1995; 61:514.
  50. Ardawi MS, Nasrat HA, BA'Aqueel HS. Calcium-regulating hormones and parathyroid hormone-related peptide in normal human pregnancy and postpartum: a longitudinal study. Eur J Endocrinol 1997; 137:402.
  51. Wagner CL, Taylor SN, Dawodu A, et al. Vitamin D and its role during pregnancy in attaining optimal health of mother and fetus. Nutrients 2012; 4:208.
  52. Hollis BW, Johnson D, Hulsey TC, et al. Vitamin D supplementation during pregnancy: double-blind, randomized clinical trial of safety and effectiveness. J Bone Miner Res 2011; 26:2341.
  53. Bikle DD, Gee E, Halloran B, Haddad JG. Free 1,25-dihydroxyvitamin D levels in serum from normal subjects, pregnant subjects, and subjects with liver disease. J Clin Invest 1984; 74:1966.
  54. Delvin EE, Arabian A, Glorieux FH, Mamer OA. In vitro metabolism of 25-hydroxycholecalciferol by isolated cells from human decidua. J Clin Endocrinol Metab 1985; 60:880.
  55. Weisman Y, Harell A, Edelstein S, et al. 1 alpha, 25-Dihydroxyvitamin D3 and 24,25-dihydroxyvitamin D3 in vitro synthesis by human decidua and placenta. Nature 1979; 281:317.
  56. Glinoer D, de Nayer P, Bourdoux P, et al. Regulation of maternal thyroid during pregnancy. J Clin Endocrinol Metab 1990; 71:276.
  57. Burrow GN, Fisher DA, Larsen PR. Maternal and fetal thyroid function. N Engl J Med 1994; 331:1072.
  58. Berghout A, Wiersinga W. Thyroid size and thyroid function during pregnancy: an analysis. Eur J Endocrinol 1998; 138:536.
  59. Muller AF, Verhoeff A, Mantel MJ, et al. Decrease of free thyroxine levels after controlled ovarian hyperstimulation. J Clin Endocrinol Metab 2000; 85:545.
  60. Fantz CR, Dagogo-Jack S, Ladenson JH, Gronowski AM. Thyroid function during pregnancy. Clin Chem 1999; 45:2250.
  61. Ain KB, Mori Y, Refetoff S. Reduced clearance rate of thyroxine-binding globulin (TBG) with increased sialylation: a mechanism for estrogen-induced elevation of serum TBG concentration. J Clin Endocrinol Metab 1987; 65:689.
  62. Dörr HG, Heller A, Versmold HT, et al. Longitudinal study of progestins, mineralocorticoids, and glucocorticoids throughout human pregnancy. J Clin Endocrinol Metab 1989; 68:863.
  63. Elsheikh A, Creatsas G, Mastorakos G, et al. The renin-aldosterone system during normal and hypertensive pregnancy. Arch Gynecol Obstet 2001; 264:182.
  64. Funder JW. Aldosterone action: fact, failure and the future. Clin Exp Pharmacol Physiol Suppl 1998; 25:S47.
  65. Thomsen JK, Fogh-Andersen N, Jaszczak P, Giese J. Atrial natriuretic peptide (ANP) decrease during normal pregnancy as related to hemodynamic changes and volume regulation. Acta Obstet Gynecol Scand 1993; 72:103.
  66. Clerico A, Del Chicca MG, Ferdeghini M, et al. Progressively elevated levels of biologically active (free) cortisol during pregnancy by a direct radioimmunological assay of diffusible cortisol in an equilibrium dialysis system. J Endocrinol Invest 1980; 3:185.
  67. Kerlan V, Nahoul K, Le Martelot MT, Bercovici JP. Longitudinal study of maternal plasma bioavailable testosterone and androstanediol glucuronide levels during pregnancy. Clin Endocrinol (Oxf) 1994; 40:263.
  68. Chang H, Brown CW, Matzuk MM. Genetic analysis of the mammalian transforming growth factor-beta superfamily. Endocr Rev 2002; 23:787.
  69. Qu J, Thomas K. Inhibin and activin production in human placenta. Endocr Rev 1995; 16:485.
  70. Petraglia F, Sawchenko P, Lim AT, et al. Localization, secretion, and action of inhibin in human placenta. Science 1987; 237:187.
  71. Minami S, Yamoto M, Nakano R. Immunohistochemical localization of inhibin/activin subunits in human placenta. Obstet Gynecol 1992; 80:410.
  72. Reis FM, D'Antona D, Petraglia F. Predictive value of hormone measurements in maternal and fetal complications of pregnancy. Endocr Rev 2002; 23:230.
  73. Florio P, Luisi S, Ciarmela P, et al. Inhibins and activins in pregnancy. Mol Cell Endocrinol 2004; 225:93.
  74. Luisi S, Florio P, Reis FM, Petraglia F. Inhibins in female and male reproductive physiology: role in gametogenesis, conception, implantation and early pregnancy. Hum Reprod Update 2005; 11:123.
  75. Muttukrishna S, George L, Fowler PA, et al. Measurement of serum concentrations of inhibin-A (alpha-beta A dimer) during human pregnancy. Clin Endocrinol (Oxf) 1995; 42:391.
  76. Malone FD, Canick JA, Ball RH, et al. First-trimester or second-trimester screening, or both, for Down's syndrome. N Engl J Med 2005; 353:2001.
  77. D'Antona D, Wallace EM, Shearing C, et al. Inhibin A and pro-alpha C inhibin in Down syndrome and normal pregnancies. Prenat Diagn 1998; 18:1122.
  78. Florio P, Luisi S, D'Antona D, et al. Maternal serum inhibin A levels may predict pregnancy outcome in women with threatened abortion. Fertil Steril 2004; 81:468.
  79. Lockwood GM, Ledger WL, Barlow DH, et al. Measurement of inhibin and activin in early human pregnancy: demonstration of fetoplacental origin and role in prediction of early-pregnancy outcome. Biol Reprod 1997; 57:1490.
  80. Florio P, Cobellis L, Luisi S, et al. Changes in inhibins and activin secretion in healthy and pathological pregnancies. Mol Cell Endocrinol 2001; 180:123.
  81. Florio P, Benedetto C, Luisi S, et al. Activin A, inhibin A, inhibin B and parturition: changes of maternal and cord serum levels according to the mode of delivery. Br J Obstet Gynaecol 1999; 106:1061.
  82. Florio P, Reis FM, Pezzani I, et al. The addition of activin A and inhibin A measurement to uterine artery Doppler velocimetry to improve the early prediction of pre-eclampsia. Ultrasound Obstet Gynecol 2003; 21:165.
  83. Florio P, Perrone S, Luisi S, et al. Activin a plasma levels at birth: an index of fetal hypoxia in preterm newborn. Pediatr Res 2003; 54:696.
  84. Florio P, Severi FM, Bocchi C, et al. Single serum activin a testing to predict ectopic pregnancy. J Clin Endocrinol Metab 2007; 92:1748.
  85. Florio P, Perrone S, Luisi S, et al. Increased plasma concentrations of activin a predict intraventricular hemorrhage in preterm newborns. Clin Chem 2006; 52:1516.
  86. Florio P, Luisi S, Bruschettini M, et al. Cerebrospinal fluid activin a measurement in asphyxiated full-term newborns predicts hypoxic ischemic encephalopathy. Clin Chem 2004; 50:2386.
  87. Florio P, Luisi S, Moataza B, et al. High urinary concentrations of activin A in asphyxiated full-term newborns with moderate or severe hypoxic ischemic encephalopathy. Clin Chem 2007; 53:520.
  88. Luisi S, Florio P, Reis FM, Petraglia F. Expression and secretion of activin A: possible physiological and clinical implications. Eur J Endocrinol 2001; 145:225.
  89. Maguer-Satta V, Bartholin L, Jeanpierre S, et al. Expression of FLRG, a novel activin A ligand, is regulated by TGF-beta and during hematopoiesis [corrected]. Exp Hematol 2001; 29:301.
  90. Ciarmela P, Florio P, Toti P, et al. Human placenta and fetal membranes express follistatin-related gene mRNA and protein. J Endocrinol Invest 2003; 26:641.
  91. Donaldson CJ, Sutton SW, Perrin MH, et al. Cloning and characterization of human urocortin. Endocrinology 1996; 137:2167.
  92. Petraglia F, Florio P, Benedetto C, et al. Urocortin stimulates placental adrenocorticotropin and prostaglandin release and myometrial contractility in vitro. J Clin Endocrinol Metab 1999; 84:1420.
  93. Florio P, Linton EA, Torricelli M, et al. Prediction of preterm delivery based on maternal plasma urocortin. J Clin Endocrinol Metab 2007; 92:4734.
  94. Florio P, Torricelli M, Galleri L, et al. High fetal urocortin levels at term and preterm labor. J Clin Endocrinol Metab 2005; 90:5361.
  95. Simoncini T, Apa R, Reis FM, et al. Human umbilical vein endothelial cells: a new source and potential target for corticotropin-releasing factor. J Clin Endocrinol Metab 1999; 84:2802.
  96. Florio P, Torricelli M, De Falco G, et al. High maternal and fetal plasma urocortin levels in pregnancies complicated by hypertension. J Hypertens 2006; 24:1831.
  97. Butte NF. Carbohydrate and lipid metabolism in pregnancy: normal compared with gestational diabetes mellitus. Am J Clin Nutr 2000; 71:1256S.
  98. Homko CJ, Sivan E, Reece EA, Boden G. Fuel metabolism during pregnancy. Semin Reprod Endocrinol 1999; 17:119.
  99. Kim H, Toyofuku Y, Lynn FC, et al. Serotonin regulates pancreatic beta cell mass during pregnancy. Nat Med 2010; 16:804.
  100. Karnik SK, Chen H, McLean GW, et al. Menin controls growth of pancreatic beta-cells in pregnant mice and promotes gestational diabetes mellitus. Science 2007; 318:806.
  101. Zhang H, Zhang J, Pope CF, et al. Gestational diabetes mellitus resulting from impaired beta-cell compensation in the absence of FoxM1, a novel downstream effector of placental lactogen. Diabetes 2010; 59:143.
  102. Handwerger S, Freemark M. The roles of placental growth hormone and placental lactogen in the regulation of human fetal growth and development. J Pediatr Endocrinol Metab 2000; 13:343.
  103. Barbour LA. New concepts in insulin resistance of pregnancy and gestational diabetes: long-term implications for mother and offspring. J Obstet Gynaecol 2003; 23:545.
  104. Yamashita H, Shao J, Friedman JE. Physiologic and molecular alterations in carbohydrate metabolism during pregnancy and gestational diabetes mellitus. Clin Obstet Gynecol 2000; 43:87.
  105. Catalano PM, Kirwan JP, Haugel-de Mouzon S, King J. Gestational diabetes and insulin resistance: role in short- and long-term implications for mother and fetus. J Nutr 2003; 133:1674S.
  106. Hernandez TL, Friedman JE, Van Pelt RE, Barbour LA. Patterns of glycemia in normal pregnancy: should the current therapeutic targets be challenged? Diabetes Care 2011; 34:1660.
  107. D'Anna R, Scilipoti A, Giordano D, et al. myo-Inositol supplementation and onset of gestational diabetes mellitus in pregnant women with a family history of type 2 diabetes: a prospective, randomized, placebo-controlled study. Diabetes Care 2013; 36:854.
  108. Ghazeeri GS, Nassar AH, Younes Z, Awwad JT. Pregnancy outcomes and the effect of metformin treatment in women with polycystic ovary syndrome: an overview. Acta Obstet Gynecol Scand 2012; 91:658.
  109. Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 2004; 89:2548.
  110. Brizzi P, Tonolo G, Esposito F, et al. Lipoprotein metabolism during normal pregnancy. Am J Obstet Gynecol 1999; 181:430.
  111. Wiznitzer A, Mayer A, Novack V, et al. Association of lipid levels during gestation with preeclampsia and gestational diabetes mellitus: a population-based study. Am J Obstet Gynecol 2009; 201:482.e1.
  112. Piechota W, Staszewski A. Reference ranges of lipids and apolipoproteins in pregnancy. Eur J Obstet Gynecol Reprod Biol 1992; 45:27.
  113. Herrera E. Metabolic adaptations in pregnancy and their implications for the availability of substrates to the fetus. Eur J Clin Nutr 2000; 54 Suppl 1:S47.
  114. Napoli C, Palinski W. Maternal hypercholesterolemia during pregnancy influences the later development of atherosclerosis: clinical and pathogenic implications. Eur Heart J 2001; 22:4.
  115. Fanciulli G, Delitala A, Delitala G. Growth hormone, menopause and ageing: no definite evidence for 'rejuvenation' with growth hormone. Hum Reprod Update 2009; 15:341.
  116. Paulsen SK, Pedersen SB, Fisker S, Richelsen B. 11Beta-HSD type 1 expression in human adipose tissue: impact of gender, obesity, and fat localization. Obesity (Silver Spring) 2007; 15:1954.
  117. Hauguel-de Mouzon S, Lepercq J, Catalano P. The known and unknown of leptin in pregnancy. Am J Obstet Gynecol 2006; 194:1537.
  118. Ladyman SR, Augustine RA, Grattan DR. Hormone interactions regulating energy balance during pregnancy. J Neuroendocrinol 2010; 22:805.
  119. Ladyman SR, Grattan DR. Suppression of leptin receptor messenger ribonucleic acid and leptin responsiveness in the ventromedial nucleus of the hypothalamus during pregnancy in the rat. Endocrinology 2005; 146:3868.
  120. Henson MC, Castracane VD. Leptin in pregnancy: an update. Biol Reprod 2006; 74:218.
  121. McIntyre HD, Chang AM, Callaway LK, et al. Hormonal and metabolic factors associated with variations in insulin sensitivity in human pregnancy. Diabetes Care 2010; 33:356.
  122. Arner P. Insulin resistance in type 2 diabetes -- role of the adipokines. Curr Mol Med 2005; 5:333.
  123. Lepercq J, Challier JC, Guerre-Millo M, et al. Prenatal leptin production: evidence that fetal adipose tissue produces leptin. J Clin Endocrinol Metab 2001; 86:2409.
  124. Zavalza-Gómez AB, Anaya-Prado R, Rincón-Sánchez AR, Mora-Martínez JM. Adipokines and insulin resistance during pregnancy. Diabetes Res Clin Pract 2008; 80:8.
  125. Chan TF, Yuan SS, Chen HS, et al. Correlations between umbilical and maternal serum adiponectin levels and neonatal birthweights. Acta Obstet Gynecol Scand 2004; 83:165.
  126. Miller RA, Chu Q, Le Lay J, et al. Adiponectin suppresses gluconeogenic gene expression in mouse hepatocytes independent of LKB1-AMPK signaling. J Clin Invest 2011; 121:2518.
  127. Ahlsson F, Diderholm B, Ewald U, et al. Adipokines and their relation to maternal energy substrate production, insulin resistance and fetal size. Eur J Obstet Gynecol Reprod Biol 2013; 168:26.
  128. Jackson AA. Nutrients, growth, and the development of programmed metabolic function. Adv Exp Med Biol 2000; 478:41.
  129. Heenan AP, Wolfe LA, Davies GA, McGrath MJ. Effects of human pregnancy on fluid regulation responses to short-term exercise. J Appl Physiol (1985) 2003; 95:2321.